CPT 81206 BCR‑ABL1 Reimbursement & Policy

CPT code 81206 identifies molecular testing for the BCR/ABL1 major breakpoint fusion gene, a clinically important marker in hematologic malignancies such as chronic myeloid leukemia and some acute leukemias. This test can be reported as a qualitative assay to detect the presence of the fusion or as a quantitative assay to measure transcript levels, and it informs diagnosis, monitoring of disease burden, and treatment response nationally. The code represents a specialized laboratory service performed by trained molecular pathology personnel using nucleic acid-based methods.

Key payers discussed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise presentation of clinical context, typical sites of service, and the role of this test in patient management. The publication also outlines payer coverage considerations, common modifiers encountered, and related administrative details where available. Benchmarks and policy updates are summarized to aid billing and compliance staff in understanding reimbursement and documentation expectations. Data not available in the input is noted where applicable.

Billing Code Overview

CPT code 81206 describes molecular diagnostic testing for the BCR/ABL1 major breakpoint fusion gene on chromosome 22. The procedure evaluates breakage and reformation of the altered gene sequence and can be performed as a qualitative assay (detecting presence of the fusion gene) or a quantitative assay (measuring the amount of each fusion transcript).

Service Type: Molecular pathology / molecular diagnostic testing

Typical Site of Service: Clinical laboratory or hospital molecular diagnostics laboratory

Clinical Context

A typical patient is an adult with suspected or confirmed chronic myeloid leukemia (CML) or another myeloproliferative neoplasm being evaluated for the BCR-ABL1 fusion gene. The clinician (hematologist/oncologist) orders molecular testing to detect and/or quantify the BCR-ABL1 major breakpoint transcript to: confirm diagnosis, establish baseline disease burden, or monitor response to tyrosine kinase inhibitor therapy. A peripheral blood or bone marrow specimen is collected in the outpatient clinic or inpatient ward and sent to a molecular pathology laboratory. The laboratory performs qualitative reverse-transcription PCR to identify the presence of the BCR-ABL1 fusion and/or quantitative real-time PCR to measure transcript level (e.g., international scale percent or copy number) for longitudinal monitoring. Results are returned to the ordering provider and used to guide diagnosis, risk stratification, and treatment decisions.

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	Use when billing separately for the interpretive/professional component of the test if split billing applies.
`TC`	Technical component	Use when billing only the technical component (laboratory processing) of the test.

Taxonomy Code	Specialty	Notes
`207RH0000X`	Hematology	Ordering provider specialty commonly managing CML and ordering BCR-ABL1 testing.
`2085P0202X`	Pediatric Hematology-Oncology	Performs and coordinates testing for pediatric patients with suspected leukemias.
`207L00000X`	Medical Oncology	Oncology specialists who monitor molecular response to therapy.
`363L00000X`	Clinical Pathology	Laboratory/pathology specialists overseeing molecular diagnostic testing.
`207K00000X`	Hematopathology	Subspecialty interpreting hematologic molecular tests and integrating results.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C92.1`	Chronic myelogenous leukemia	Primary diagnosis for which BCR-ABL1 testing is performed to confirm disease and monitor therapy.
`C92.10`	Chronic myelogenous leukemia not having achieved remission	Used when assessing molecular response or persistent disease.
`C92.11`	Chronic myelogenous leukemia in remission	Used to document monitoring of BCR-ABL1 transcript levels during remission surveillance.
`D47.1`	Chronic myeloproliferative disease	Broader category where BCR-ABL1 testing helps distinguish CML from other myeloproliferative neoplasms.
`R79.9`	Abnormal clinical finding, unspecified	May be used as a nonspecific reason when ordering molecular testing for abnormal blood counts pending diagnosis.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`81206`	BCR-ABL1 (major breakpoint) gene sequence analysis; qualitative or quantitative	Primary molecular test to detect/measure the BCR-ABL1 fusion transcript for diagnosis and monitoring of CML.
`80750`	Sequence analysis; DNA, any method, 1-250 bp (eg, sequencing of small targets)	May be used in laboratories for confirmatory sequencing of breakpoints or variant characterization when needed.
`88240`	Flow cytometry, single tumor marker, each marker	Often performed alongside molecular testing to characterize immunophenotype in leukemias at diagnosis.
`88182`	Cytogenetic studies, fluorescent in situ hybridization (FISH) for single probe	FISH for BCR-ABL translocation is commonly performed in parallel for cytogenetic confirmation.
`81207`	BCR-ABL1 (minor breakpoint) gene sequence analysis; qualitative or quantitative	Related molecular assay for alternative BCR-ABL1 breakpoints that may be ordered if major breakpoint testing is negative but suspicion remains.

OpenPayer

Summary & Overview

CPT 81206: BCR/ABL1 Major Breakpoint Molecular Test